September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ancestry, beta-zone parapapillary atrophy (bPPA), and visual field progression in ocular hypertensive eyes in the African Descent and Glaucoma Evaluation Study (ADAGES)
Author Affiliations & Notes
  • Jeremy Reimann
    Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • James Murphy
    Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • Chad Kaplan
    Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • C Gustavo De Moraes
    Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • Alon Skaat
    Ophthalmology, Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv , Israel
  • Lama Al-Aswad
    Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • Christopher A Girkin
    Ophthalmology, School of Medicine, University of Alabama, Birmingham, Birmingham, Alabama, United States
  • Felipe A Medeiros
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, San Diego, California, United States
  • Robert N Weinreb
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, San Diego, California, United States
  • Linda M Zangwill
    Ophthalmology, Hamilton Glaucoma Center, University of California, San Diego, San Diego, California, United States
  • Jeffrey M Liebmann
    Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Jeremy Reimann, None; James Murphy, None; Chad Kaplan, None; C Gustavo De Moraes, National Eye Institute (F), Research to Prevent Blindness (F); Alon Skaat, None; Lama Al-Aswad, None; Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EySight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F); Felipe Medeiros, Alcon (C), Allergan (F), Allergan (C), Ametek (F), Ametek (C), Bausch+Lomb (F), Carl Zeiss Meditec (F), Carl Zeiss Meditec (C), Carl Zeiss Meditec (R), Heidelberg Engineering (F), Heidelberg Engineering (C), Sensimed (F), Topcon (F); Robert Weinreb, Alcon (C), Allergan (C), Amatek (C), Bausch+Lomb (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Carl Zeiss Meditech (C), Forsight (C), Genentech (F), Heidelberg Engineering (F), Konan (F), National Eye Institute (F), Neurovision (F), Optovue (F), Quark (F), Reichert (F), Tomey (F), Topcon (C), Topcon (F), Valeant (C); Linda Zangwill, Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Heidelberg Engineering, GmbH (F), Optovue Inc (F), Optovue Inc (R), Quark (F), Topcon Medical Systems Inc. (F); Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Bausch+Lomb (C), Bausch+Lomb (F), Carl Zeiss Meditech, Inc. (C), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (E), Diopysis, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc. (C), National Eye Institute (F), New York Glaucoma Research Institute (F), Optovue, Inc. (F), Quark Pharmaceuticals, Inc. (C), Reichert, Inc. (C), Reichert, Inc. (F), Sensimed, Inc. (C), SOLX, Inc. (F), SOLX, Inc. (E), Sustained Nano System (E), Sustained Nano System (P), Topcon, Inc. (F), Valeant Pharmaceuticals, Inc. (C)
  • Footnotes
    Support  P30EY022589 Eyesight Foundation of Alabama; Alcon Laboratories Inc.; Allergan Inc.; Pfizer Inc.; Merck Inc.; Santen Inc.; and the Edith C. Blum Research Fund of the New York Glaucoma Research Institute, New York, NY, Unrestricted grant from Research to Prevent Blindness, New York, New York; Shirlee and Bernard Brown Research Laboratory
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 356. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jeremy Reimann, James Murphy, Chad Kaplan, C Gustavo De Moraes, Alon Skaat, Lama Al-Aswad, Christopher A Girkin, Felipe A Medeiros, Robert N Weinreb, Linda M Zangwill, Jeffrey M Liebmann; Ancestry, beta-zone parapapillary atrophy (bPPA), and visual field progression in ocular hypertensive eyes in the African Descent and Glaucoma Evaluation Study (ADAGES). Invest. Ophthalmol. Vis. Sci. 2016;57(12):356.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The Ocular Hypertension Treatment Study (OHTS) recently reported that bPPA area and its enlargement are not significantly associated with conversion to glaucoma.[1] We tested the hypotheses that (i) bPPA at baseline and its enlargement during follow-up are associated with faster VF progression and (ii) this association differs between African Descent (AD) and European Descent (ED) subjects with OHT.

Methods : From the African Descent and Glaucoma Evaluation Study (ADAGES), 276 eyes of AD (106) and ED (170) patients with OHT and who had at least one follow-up optic disc photo were included. Two graders masked to clinical and race data reviewed the baseline and last disc photos and graded them for the presence of bPPA at baseline and ‘bPPA progression’ (development or enlargement). We investigated the relationships between (i) the presence of bPPA at baseline and ancestry group, (ii) bPPA progression and ancestry group; and (iii) bPPA at baseline and its enlargement and rates of VF progression. Mixed-effects linear models were tested with VF mean deviation as dependent variable and ‘Time’ (alone and with interaction terms) as independent variables. Interaction terms (‘Race*Baseline bPPA’ and ‘Race*bPPA Progression’) were included to test the hypothesis that the relationship between baseline bPPA and bPPA progression vs. rates of VF progression differ between ancestry groups.

Results : The prevalence of bPPA at baseline was not different between AD and ED ocular hypertensive eyes (OR= 1.08, 95% CI= 0.63 to 1.87, P=0.765). There was also no difference in bPPA progression between the two groups (OR=0 .22, 95% CI= 0.02 to 2.40, P= 0.216). Neither the presence of bPPA at baseline (P=0.820) nor its progression (P=0.807) were associated with faster VF progression in ED and AD eyes.

Conclusions : We confirmed the findings of the OHTS [1] in a cohort of AD and ED patients with OHT. Moreover, the lack of a significant association between bPPA and its enlargement with VF progression held true in both ancestry groups. Our data (from an accompanying abstract) suggests that this relationship may change once glaucomatous damage is established.

[1] - OHTS. Ophthalmology. 2015; 122:79-86

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×